ArticleAnimal models and experimental medicine2025
Pimobendan alleviates myocyte apoptosis and fibrosis associated with mitral regurgitation by targeting endoplasmic reticulum stress.
Article in Animal models and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pimobendan alleviates myocyte apoptosis and fibrosis associated with mitral regurgitation by targeting endoplasmic reticulum stress.Animal models and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundEndoplasmic reticulum (ER) stress is an important factor in the development of numerous cardiovascular disorders; nevertheless, the association between ER stress and mitral regurgitation (MR) remains inadequately characterized. The molecular mechanism of pimobendan (PIMO) that contributes to the delay in congestive heart failure (CHF) in MR associated with apoptosis and fibrosis is still unclear. Our aim was to examine the impact of PIMO on ER stress, apoptosis, and fibrosis in a chronic MR rat model.
methodsMR was surgically induced in 10 Sprague-Dawley rats, with 5 serving as sham operation controls. At 8 weeks postsurgery, the MR animals were randomly allocated into two groups: MR and MR + PIMO groups. PIMO was administered twice daily through oral gavage for 4 weeks, whereas the sham and MR groups were administered similar quantities of drinking water. Echocardiography was conducted before the delivery of PIMO as a baseline measure and at the end of the study. At the end of the investigation, hearts were procured for histopathological and ER stress evaluations.
resultsPIMO significantly maintained heart function and structural remodeling in the MR animals. PIMO significantly reduced MR-induced myocyte apoptosis (p = 0.044) and fibrosis (p = 0.002) by reducing the messenger RNA expression of genes associated with ER stress (GRP78 [glucose-regulated protein 78], ATF4 [activating transcription factor 4], and CHOP [C/ERP homologous protein]) compared to the MR group (p < 0.05, p < 0.01, and p < 0.001, respectively).
conclusionPIMO demonstrated cardioprotective benefits on heart function, myocyte apoptosis, and fibrosis by regulating ER stress in an MR-induced CHF rat model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.